1. Siegler, A. J. et al. Willingness to Seek Diagnostic Testing for SARS-CoV-2 With Home, Drive-through, and Clinic-Based Specimen Collection Locations. Open Forum Infectious Diseases 7, (2020).
2. Valentine-Graves, M. et al. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection acceptability of specimen collection process and patient confidence in specimens. PLOS ONE 15, e0236775 (2020).
3. Sakhi, A. K. et al. Feasibility of self-sampled dried blood spot and saliva samples sent by mail in a population-based study. BMC Cancer 15, 265 (2015).
4. Etter, J. F., Perneger, T. V. & Ronchi, A. Collecting saliva samples by mail. Am. J. Epidemiol. 147, 141–146 (1998).
5. Garcia-Beltran, W. F. et al. Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing. Archives of Pathology & Laboratory Medicine 145, 415–418 (2020).
6. GeurtsvanKessel, C. H. et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nature Communications 11, 3436 (2020).
7. Black, M. A. et al. Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples. Journal of Immunological Methods 489, 112909 (2021).
8. Kohmer, N., Westhaus, S., Rühl, C., Ciesek, S. & Rabenau, H. F. Clinical performance of different SARS-CoV-2 IgG antibody tests. Journal of Medical Virology 92, 2243–2247 (2020).
9. Khurshid, Z. et al. Human Saliva Collection Devices for Proteomics: An Update. Int J Mol Sci 17, (2016).
10. Petrone, M. E. et al. Usability of saliva collection devices for SARS-CoV-2 diagnostics. medRxiv 2021.02.01.21250946 (2021) doi:10.1101/2021.02.01.21250946.
11. Granade, T. C. et al. Detection of antibodies to human immunodeficiency virus type 1 in oral fluids: a large-scale evaluation of immunoassay performance. Clin. Diagn. Lab. Immunol. 5, 171–175 (1998).
12. Hodinka, R. L., Nagashunmugam, T. & Malamud, D. Detection of Human Immunodeficiency Virus Antibodies in Oral Fluids. Clin. Diagn. Lab. Immunol. 5, 419–426 (1998).
13. Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Science Immunology 5, (2020).
14. Pisanic, N. et al. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. Journal of Clinical Microbiology 59, (2020).
15. Faustini, S. E. et al. Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection. medRxiv 2020.06.16.20133025 (2020) doi:10.1101/2020.06.16.20133025.
16. Heaney, C. D. et al. Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers. medRxiv 2021.01.28.21250717 (2021) doi:10.1101/2021.01.28.21250717.
17. MacMullan, M. A. et al. ELISA detection of SARS-CoV-2 antibodies in saliva. Scientific Reports 10, 20818 (2020).
18. A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older.
19. Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet 396, 1979–1993 (2020).
20. Gilbert, P. B. et al. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. 2021.08.09.21261290 https://www.medrxiv.org/content/10.1101/2021.08.09.21261290v4 (2021) doi:10.1101/2021.08.09.21261290.
21. Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. 2021.06.21.21258528 https://www.medrxiv.org/content/10.1101/2021.06.21.21258528v1 (2021) doi:10.1101/2021.06.21.21258528.
22. Johnson, M. et al. Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. Journal of Clinical Virology 130, 104572 (2020).
23. Parry, J. V. Simple and reliable salivary tests for HIV and hepatitis A and B virus diagnosis and surveillance. Ann. N. Y. Acad. Sci. 694, 216–233 (1993).
24. Gonzalez-Quintela, A. et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 151, 42–50 (2008).
25. Riis, J. L., Bryce, C. I., Stebbins, J. L. & Granger, D. A. Salivary total Immunoglobulin G as a surrogate marker of oral immune activity in salivary bioscience research. Brain, Behavior, & Immunity - Health 1, 100014 (2020).
26. Horsfall, A. C., Rose, L. M. & Maini, R. N. Autoantibody synthesis in salivary glands of Sjögren’s syndrome patients. Journal of Autoimmunity 2, 559–568 (1989).
27. Lehne, G. et al. Oral administration of a new soluble branched β-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. Clinical & Experimental Immunology 143, 65–69 (2006).
28. Gaunt, E. R., Hardie, A., Claas, E. C. J., Simmonds, P. & Templeton, K. E. Epidemiology and Clinical Presentations of the Four Human Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 3 Years Using a Novel Multiplex Real-Time PCR Method. Journal of Clinical Microbiology 48, 2940–2947 (2010).
29. Killerby, M. E. et al. Human coronavirus circulation in the United States 2014–2017. Journal of Clinical Virology 101, 52–56 (2018).
30. Westerhuis, B. M. et al. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands. medRxiv 2020.08.21.20177857 (2020) doi:10.1101/2020.08.21.20177857.
31. Jacob, J. T. et al. Risk Factors Associated With SARS-CoV-2 Seropositivity Among US Health Care Personnel. JAMA Netw Open 4, e211283 (2021).
32. Oran, D. P. & Topol, E. J. Prevalence of Asymptomatic SARS-CoV-2 Infection. Ann Intern Med 173, 362–367 (2020).
33. Milani, G. P. et al. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Scientific Reports 10, 20048 (2020).
34. Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine 26, 1200–1204 (2020).
35. Ibarrondo, F. J. et al. Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. New England Journal of Medicine 383, 1085–1087 (2020).
36. Atyeo, C. et al. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity 53, 524-532.e4 (2020).
37. MacMullan, M. A. et al. Detection of SARS-CoV-2 Antibodies in Oral Fluid Obtained Using a Rapid Collection Device. J Clin Microbiol 59, e02510-20, /jcm/59/2/JCM.02510-20.atom (2020).
38. Brandtzaeg, P. Secretory immunity with special reference to the oral cavity. Journal of Oral Microbiology 5, 20401 (2013).
39. Wu, X. & Jackson, S. Plasma and Salivary IgG Subclasses in HIV Type 1 Infection: Evidence of Both Transudation and Local Synthesis of IgG in Parotid Saliva. AIDS Research and Human Retroviruses 16, 1423–1431 (2000).
40. Strober, W., Blaese, R. M. & Waldmann, T. A. The origin of salivary IgA. The Journal of Laboratory and Clinical Medicine 75, 856–862 (1970).
41. Petherick, A. Developing antibody tests for SARS-CoV-2. The Lancet 395, 1101–1102 (2020).
42. Anand, S. et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. The Lancet 396, 1335–1344 (2020).
43. Buss, L. F. et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 371, 288–292 (2021).
44. Ng, D. L. et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nat Commun 11, 4698 (2020).
45. Uyoga, S. et al. Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science 371, 79–82 (2021).
46. Bajema, K. L. et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Internal Medicine (2020) doi:10.1001/jamainternmed.2020.7976.
47. Kwiecien, R., Kopp-Schneider, A. & Blettner, M. Concordance Analysis. Dtsch Arztebl Int 108, 515–521 (2011).